Novartis AG
Change company Symbol lookup
Select an option...
NVS Novartis AG
PFE Pfizer Inc
AGNC Agnc Investment Corp
AAPL Apple Inc
GRTYA Guaranty Corp
SATS EchoStar Corp
$DJI Dow Jones Industrials
TIKK Tel-Instrument Electronics Corp
TEAM Atlassian Corporation PLC
PAYX Paychex Inc
Go

Health Care : Pharmaceuticals | Large Cap Blend
Based in Switzerland
Company profile

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$91.41
Day's Change
1.17 (1.30%)
Bid
--
Ask
--
B/A Size
--
Day's High
91.52
Day's Low
91.01
Volume
(Light)

Today's volume of 687,966 shares is on pace to be much lighter than NVS's 10-day average volume of 2,601,086 shares.

687,966

Dr. Ellen R. Strahlman Elected to Altria's Board of Directors

4:00 am ET October 30, 2020 (BusinessWire) Print

Altria Group, Inc. (Altria) (NYSE:MO) announces that Dr. Ellen R. Strahlman will join its Board of Directors on November 2, 2020.

Dr. Strahlman served as Executive Vice President, Research & Development and Chief Medical Officer of Becton, Dickinson and Company, a leading global medical technology company, from April 2013 until her retirement in January 2018. Before joining Becton Dickinson and Company, she served as a Senior Advisor to the CEO at GlaxoSmithKline from April 2012 through March 2013, after previously serving as the Senior Vice President and Chief Medical Officer from April 2008 through March 2012. Prior to 2008, Dr. Strahlman held senior executive leadership roles in global product development and commercialization, medical affairs and business development at leading pharmaceutical and medical technology companies including Pfizer, Inc., Novartis AG, Virogen Limited, Bausch & Lomb, Inc. and Merck & Co., Inc. She currently serves as a director of Syncona Limited having previously served as a director of Syncona Partners, LLC.

Dr. Strahlman will be a member of the Finance and Innovation Committees.

Altria's Profile

Altria's wholly owned subsidiaries include Philip Morris USA Inc. (PM USA), U.S. Smokeless Tobacco Company LLC (USSTC), John Middleton Co. (Middleton), Ste. Michelle Wine Estates Ltd. (Ste. Michelle) and Philip Morris Capital Corporation (PMCC). Altria owns an 80% interest in Helix Innovations LLC (Helix). Altria holds equity investments in Anheuser-Busch InBev SA/NV (ABI), JUUL Labs, Inc. (JUUL) and Cronos Group Inc. (Cronos).

The brand portfolios of Altria's tobacco operating companies include Marlboro(R), Black & Mild(R), Copenhagen(R), Skoal(R) and on!(R). Ste. Michelle produces and markets premium wines sold under various labels, including Chateau Ste. Michelle(R), 14 Hands(R) and Stag's Leap Wine Cellars(TM), and it imports and markets Antinori(R), Champagne Nicolas Feuillatte(TM) and Villa Maria Estate(TM) products in the United States. Trademarks and service marks related to Altria referenced in this release are the property of Altria or its subsidiaries or are used with permission.

More information about Altria is available at altria.com and on the Altria Investor app, or follow Altria on Twitter, Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201030005308/en/

SOURCE: Altria Group, Inc.">

Altria Client Services
Investor Relations
(804) 484-8222

Altria Client Services
Media Affairs
(804) 484-8897
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.